- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 759-773 of
1,261 results
2095 Exhibit: EX2095 Evans, LM, et al, A population adjusted indirect comparison ...
Document
IPR2023-00724, No. 2095 Exhibit - EX2095 Evans, LM, et al, A population adjusted indirect comparison of cardiovascular benefits of once weekly subcutaneous semaglutide and dulaglutide in ...
|
|
Cite Document
2364 Exhibit: EX2364 US Food Drug Administration, DrugsFDA, Glucotrol®
Document
IPR2023-00724, No. 2364 Exhibit - EX2364 US Food Drug Administration, DrugsFDA, Glucotrol® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
1162 Exhibit: Exhibit 1162 Rizzo
Document
IPR2023-00724, No. 1162 Exhibit - Exhibit 1162 Rizzo (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1161 Exhibit: Exhibit 1161 Zeeuw
Document
IPR2023-00724, No. 1161 Exhibit - Exhibit 1161 Zeeuw (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1165 Exhibit: Exhibit 1165 41st Orange Book
Document
IPR2023-00724, No. 1165 Exhibit - Exhibit 1165 41st Orange Book (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1295 Exhibit: Exhibit 1295 032 App
Document
IPR2023-00724, No. 1295 Exhibit - Exhibit 1295 032 App (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2438 Exhibit: EX2438 Hoerman, J, “Tanzeum albiglutide Discontinued After FDA W...
Document
IPR2023-00724, No. 2438 Exhibit - EX2438 Hoerman, J, “Tanzeum albiglutide Discontinued After FDA Warns of Risk of Anaphylaxis Reaction,” httpstrulawcomfdatanzeum albiglutide anaphylaxi...
|
|
Cite Document
2452 Exhibit: EX2452 Synjardy Prescribing Information rev Dec 2017
Document
IPR2023-00724, No. 2452 Exhibit - EX2452 Synjardy Prescribing Information rev Dec 2017 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2528 Exhibit: EX2528 Eli Lilly Co, SEC Form 10 Q for the Quarter Ended March 31,...
Document
IPR2023-00724, No. 2528 Exhibit - EX2528 Eli Lilly Co, SEC Form 10 Q for the Quarter Ended March 31, 2023 Apr 27, 2023 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2507 Exhibit: EX2507 Novo Nordisk, Financial report for the period 1 January 2021...
Document
IPR2023-00724, No. 2507 Exhibit - EX2507 Novo Nordisk, Financial report for the period 1 January 2021 to 30 June 2021 Aug 4, 2021 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2467 Exhibit: EX2467 US Food Drug Administration, DrugsFDA, Steglujan
Document
IPR2023-00724, No. 2467 Exhibit - EX2467 US Food Drug Administration, DrugsFDA, Steglujan (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2401 Exhibit: EX2401 US Food Drug Administration, DrugsFDA, Janumet®
Document
IPR2023-00724, No. 2401 Exhibit - EX2401 US Food Drug Administration, DrugsFDA, Janumet® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
1168 Exhibit: Exhibit 1168 US6899699
Document
IPR2023-00724, No. 1168 Exhibit - Exhibit 1168 US6899699 (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1300 Exhibit: Exhibit 1300 Bantle Decl
Document
IPR2023-00724, No. 1300 Exhibit - Exhibit 1300 Bantle Decl (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2555 Exhibit: EX2555 REDACTED Transcript of July 19, 2024 Deposition of DeFore...
Document
IPR2023-00724, No. 2555-2 Exhibit - EX2555 REDACTED Transcript of July 19, 2024 Deposition of DeForest McDuff (P.T.A.B. Aug. 5, 2024)
|
|
Cite Document
